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Abstract 
In 2015, the American company Turing Pharmaceuticals increased the price of 
the drug Daraprim by 5,000 percent overnight. Politicians and healthcare repre-
sentatives accused Turing’s CEO, Martin Shkreli, of having harmed both vulne-
rable patient groups and the healthcare system. The present article aims to attain 
an understanding of how Shkreli justified increasing the price and restricting the 
distribution of the drug Daraprim. Statements made by Shkreli in four video in-
terviews were analyzed on the basis of Sykes and Matza’s (1957) theoretical 
framework of neutralization techniques. All techniques of neutralization were 
identified. Shkreli shifted the blame to other actors, denied the existence of vic-
tims and of harm to the nation’s healthcare system, characterized his accusers as 
corrupt, and portrayed profit maximization as a more important goal than public 
health. 
 År 2015 höjde det amerikanska företaget Turing Pharmaceuticals priset på 
läkemedlet Daraprim med 5000% över en natt. Politiker och representanter inom 
sjukvården beskyllde Turings VD, Martin Shkreli, för att ha skadat både sårbara 
patientgrupper och sjukvårdssystemet. Den aktuella artikeln syftar till att nå en 
förståelse av hur Shkreli rättfärdigade prishöjningen och den begränsade distri-
butionen av Daraprim. Uttalanden från Shkreli i fyra intervjuer analyserades en-
ligt Sykes och Matzas (1957) teoretiska ramverk neutralisationstekniker. Samtli-
ga tekniker identifierades. Shkreli skuldbelade andra aktörer, förnekade existen-
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sen av offer samt skada på det amerikanska sjukvårdssystemet, skildrade för-
dömarna som korrupta och framställde vinstmaximering som ett viktigare mål än 
folkhälsa.  
Introduction 
The pharmaceutical industry has been viewed as being involved in systematic and 
harmful corporate conduct that traditional legal solutions have continually failed 
to suppress (Braithwaite, 1984: 308f). Despite the negative consequences of such 
corporate conduct, there has been a lack of studies on the ethical standards found 
within the pharmaceutical industry (Zetterqvist, Merlo & Mulinari, 2015: 3). One 
finding from the few studies on harmful corporate conduct in the drug industry 
that have been conducted in a Scandinavian context has been that the self-
regulatory system of the Swedish pharmaceutical industry is ineffective in re-
straining ongoing acts of misleading advertising (Zetterqvist et al., 2015; Zet-
terqvist & Mulinari, 2013). From an international perspective, important contri-
butions to the field have been made by Braithwaite (1984, 1993). According to 
Braithwaite (1984: 159, 166), drug patents provide manufacturers with the legal 
means to engage in arbitrary drug pricing, which in turn shows the ineffective-
ness of antitrust laws in preventing drug monopolies. Drug industry representa-
tives have long claimed that high prices for life-saving medications are necessary 
due to the cost of researching and developing drugs (Dukes, Braithwaite & 
Moloney, 2014: 215). A study by Kesselheim, Avorn, and Sarpatwari (2016: 
863) challenged this longstanding claim in noting that major pharmaceutical 
companies invested between 10 and 20 percent of their revenue in research and 
development. In addition, pharmaceutical companies have tried to obtain tax ben-
efits by categorizing marketing expenditures as research and development in 
company records (Dukes et al., 2014: 216).  
 The subject of the pricing of life-saving drugs received a great deal of atten-
tion in both the political and public discourse in 2015 when the American drug 
company Turing Pharmaceuticals acquired the marketing rights for the drug Dar-
aprim and raised the price per pill from 13.50 US dollars to 750 US dollars (Car-
rier, Levidow & Kesselheim, 2017: 1380, 1407; Hurst, 2017: 105f; New York 
Times, 2015a), an overnight price increase of approximately 5,000 percent. At 
the time of the price increase, Daraprim had been on the market for 62 years and 
there were no effective alternative treatments available (Carrier et al., 2017: 1387, 
1404). Further, the price increase meant skyrocketing costs for individuals in 
need of Daraprim to treat the life-threatening infectious disease toxoplasmosis, as 
well as certain types of cancer or HIV/AIDS (First, 2019: 727; Penn Bioethics, 
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2015). At the center of heavy criticism from media outlets was Martin Shkreli, 
the chief executive officer [CEO] of Turing, who became notorious under the 
nicknames “Pharma Bro” and the “Bad Boy of Pharmaceuticals” (New York 
Times, 2015b, 2018). Shkreli has been described as an intelligent young man 
raised under conditions of economic hardship by his Albanian immigrant parents 
in Brooklyn (Ibid.). Having come a long way from this background, as CEO at 
the age of 32, Shkreli came to be portrayed as the face of industry greed (New 
York Times, 2015b).  
 Turing was accused by the public of having committed a crime against the 
human right to health (Penn Bioethics, 2015). The accusation was not without 
merit, since pyrimethamine, sold under the name Daraprim in America, was in-
cluded on the World Health Organization’s (2015: 17) list of the minimum medi-
cine required for a basic healthcare system. The Democratic presidential candi-
date Hillary Clinton accused Shkreli of price gouging (Hurst, 2017: 106), while 
the HIV Medicine Association and the Infectious Diseases Society of America 
formulated a letter to Turing warning that the price increase would cause harm to 
a vulnerable patient group as well as the American healthcare system (Calder-
wood, & Adimora, 2015, September 8). This letter not only addressed the price 
increase but also issues regarding the distribution of Daraprim (Ibid.). According 
to Carrier et al. (2017: 1381, 1385), Turing altered the drug’s distribution scheme 
into the more restrictive Daraprim Direct system several months prior to the price 
increase, which placed Turing in complete control of the distribution chain. 
Walgreens Specialty Pharmacy became the only source for obtaining supplies or 
prescriptions for Daraprim, which could be viewed as a strategy to injure compe-
tition from rivals in the drug market (Carrier et al., 2017: 1381, 1403). This 
change also resulted in a shortage of the drug at hospitals, local pharmacies, and 
other general wholesalers. In addition, Turing made it impossible for anyone oth-
er than individuals and organizations registered as clients of Daraprim Direct to 
obtain the drug (Ibid.). The requirement to be a registered client of Turing’s con-
trolled distribution system constituted exclusionary conduct on the drug market, 
since it prevented competitor drug companies from obtaining samples of the ac-
tive ingredients required for manufacturing inexpensive generic drugs and having 
those generics approved by the national Food and Drug Administration (Ibid: 
1387, 1399f).  
 In the end, no legal actions were brought concerning Turing’s price increase 
for Daraprim (New York Times, 2018). Instead, Martin Shkreli was sentenced to 
seven years’ imprisonment for fraud. These crimes were committed during the 
period when Shkreli held his former position, as CEO of the pharmaceutical 
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company Retrophin, where he secretly controlled company shares and lied to in-
vestors about hedge funds. In addition to the prison sentence, Shkreli had to pay a 
fine of 75,000 US dollars and 7.36 million US dollars in forfeiture. Further, a 5 
million US dollar bail was withdrawn when it was revealed that Shkreli had writ-
ten a post on Facebook in which he offered 5,000 US dollars to anyone grabbing 
a strand of hair from Hillary Clinton’s head (Washington Post, 2017). In short, 
the Daraprim scandal led to Shkreli being transformed into a public villain (New 
York Times, 2015b). 
 In view of the Daraprim scandal, questions arise regarding harmful corporate 
conduct. The aim of this article is to attain an understanding of how an individual 
in a leadership position in the pharmaceutical industry can make decisions that 
negatively affect patients suffering from life-threatening diseases, which make 
them wholly dependent on the company’s product. To investigate these strate-
gies, statements made by Shkreli in interviews will be analyzed on the basis of 
Sykes and Matza’s (1957) theoretical framework of neutralization techniques, 
and frame analysis. The question at hand is what justifications did Martin Shkreli, 
the CEO of Turing Pharmaceuticals, give for increasing the price and restricting 
the distribution of the drug Daraprim when he was accused of causing social 
harm to vulnerable patient groups and the healthcare system? 
Corporate crime & social harm 
In traditional criminology, crime has been defined as an act punishable by crimi-
nal law (Rothe & Kauzlarich, 2016: 3). Edwin H. Sutherland (1940: 2f) chal-
lenged this perception when introducing the concept of white-collar crime in 
1940 to describe criminal behavior that occurs within the fields of medicine and 
banking and in the political sphere. In addition, Sutherland’s (1940: 5f) definition 
of white-collar crime included violations against civil or administrative laws. 
During the eighties, Sutherland’s concept came to evolve when researchers such 
as Clinard and Yeager (2010) applied the term corporate crime to describe crimi-
nal behavior in the corporate world. Since then, many other important contribu-
tions in the field of corporate crime have been made (for example, see Bittle, 
2016; Braithwaite, 1984; Croall 2007; Glasbeek, 2002). The definition of corpo-
rate crime used by Braithwaite (1984: 6) involves conduct by corporations, or 
their employees, that is punishable by law. According to Braithwaite (Ibid.), it is 
whether the conduct is punishable that is of interest, rather than whether or not 
the conduct in question was punished.  
 Even though the price increase and restrictive distribution of Daraprim did not 
lead to any legal convictions, Turing’s monopoly power over the drug and the 
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corporation’s exclusionary conduct against competitors on the market has been 
considered to be strong reasons for investigating a potential antitrust claim (Car-
rier et al., 2017: 1407; First, 2019: 730). However, the fact that no legal actions 
have been brought concerning Turing’s conduct may lead some to believe that 
this type of behavior of pharmaceutical companies is legal and therefore irrele-
vant to criminology. Even when reactions from the criminal justice system are 
absent, unethical behavior by pharmaceutical companies is of interest to crimi-
nology, as well as society at large, since they may still cause great social harm. 
Pemberton (2007: 36f) has defined social harm as the study of modes of social 
organization that produce harm to the needs and well-being of human lives. Ac-
cording to Hillyard and Tombs (2007: 15ff), the concept of social harm encom-
passes activities by organizations that expose individuals to physical or financial 
harm on a grand scale, events that criminal law may fail to capture when focusing 
on individual street crimes that affect fewer individuals. In this article, the broad 
definition of social harm will be applied to capture the reported harm inflicted on 
consumers, the healthcare system and the American drug market by Turing’s 
business activities (Calderwood & Adimora, 2015, September 8; Carrier et al., 
2017: 1381, 1407).  
Theoretical framework  
Sykes and Matza (1957: 666f) developed their theoretical framework on the tech-
niques of neutralization to explain how individuals who commit criminal acts ra-
tionalize their actions in order to neutralize social control. Such rationalizations 
are perceived by these individuals as legitimate ways of justifying illegal acts to 
show the absence of intent, protect themselves from blame and escape sanctions. 
According to Sykes and Matza (Ibid.), the techniques of neutralization can be uti-
lized in order to avoid feeling guilty or, when applied prior to the act, to make the 
crime possible in the first place.  
 Sykes and Matza (1957: 667ff) proposed five central techniques of neutraliza-
tion; denial of responsibility, denial of injury, denial of the victim, condemnation 
of the condemners and the appeal to higher loyalties. These techniques are de-
scribed in more detail in the results section and will be applied in the present arti-
cle to explain the defense strategies employed by Shkreli when confronted as a 
result of his decision-making during the Daraprim scandal. 
Previous research 
The applicability Sykes and Matza’s (1957:667) techniques of neutralization in 
the context of corporate actors can be questioned since the framework was origi-
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nally developed to explain juvenile delinquency. However, the techniques of neu-
tralization has been viewed as a contribution to the understanding of how indi-
viduals within organizational settings minimize or deny the harmful consequenc-
es of their decision-making (Rothe & Kauzlarich, 2016: 56). Numerous studies of 
the defense strategies employed by corporate actors that commit harmful acts 
have applied the theoretical framework. For example, techniques of neutralization 
have been applied by Benson (1985: 591, 599ff) in a qualitative study of white-
collar offenders convicted for antitrust violations, fraud, embezzlement and tax 
violations. Benson (Ibid.) found a variety of strategies employed to deny crimi-
nality in the participants’ accounts, with antitrust violators portraying their crimi-
nal acts as routine business practice, criticizing the motives of prosecutors and 
referring to their loyalty towards the organizational environment. The latter strat-
egy was further explored by Schoultz and Flyghed (2016: 193) in a study in 
which the authors found that Swedish companies accused of criminal activities 
attempted to deflect allegations by framing their activities as being responsible 
and beneficial to society. 
 Previous research on techniques of neutralization in the pharmaceutical indus-
try is scarce. One study by Piquero, Tibbetts and Blankenship (2005: 180f), in 
which MBA students participated in a hypothetical scenario, found higher levels 
of the neutralization techniques denial of responsibility and denial of potential in-
jury to be positively associated with higher levels of willingness to make unethi-
cal corporate decisions in relation to a dangerous drug (Ibid.). A later study by 
Vieraitis, Piquero, Piquero, Tibbetts and Blankenship (2012) focused on gender 
differences in a similar scenario. These two studies notwithstanding, there is still 
a lack of research on how individuals in a leadership position in the pharmaceuti-
cal industry might justify harmful corporate behavior.  
Method & material 
Since the number of written interviews with Martin Shkreli located in media ar-
chives was very small, a search for audiovisual media was employed utilizing the 
YouTube search engine with the search term “Shkreli interview”. These search 
terms resulted in a large number of videos, many of which were repeated uploads 
of identical videos. After reviewing the first 50 videos in the search results, four 
videos were selected for analysis and the full-length version of each interview 
was found (Bloomberg, 2016; CNBC, 2015; Forbes, 2015; Vice, 2016). The 
length of the interviews ranged from 5.57 minutes to 18.44 minutes. The selec-
tion of videos was based on the criterion that they included responses from 
Shkreli to questions regarding the Daraprim scandal and criminal activity or caus-
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ing harm. The rationale behind this inclusion criteria was to collect interviews 
that portrayed how Shkreli replied when Turing’s conduct was questioned in rela-
tion to the Daraprim scandal.  
 In order to reveal how Shkreli portrayed the Daraprim scandal when confront-
ed, his statements were transcribed verbatim and analyzed using the frame analy-
sis method. Initially formulated by Erving Goffman (1974), frame analysis in-
volves an interpretative analysis of discourses with the goal of uncovering hege-
monic structures of meaning within data (Koenig, 2006: 62). This method is pri-
marily focused on the intentional and strategic framing of language, collective be-
liefs or political demands in order to negotiate desired outcomes or to defend 
against opponents (Bacchi, 2005: 203f). The decision to utilize frame analysis 
was based on the prior use of the method in studies on the techniques employed 
by corporations in the face of allegations of wrongdoing (Schoultz & Flyghed, 
2016: 189). The coding process was guided by the five techniques of neutraliza-
tion and these techniques were identified in the empirical material by comparing 
the framework to the responses made by Shkreli. For example, replies by Shkreli 
that shifted the blame for any wrongdoings were coded as “denial of responsibil-
ity”. In contrast, statements were coded as “appeal to higher loyalties” if the harm 
caused was acknowledged, but at the same time justified by referring to a prioriti-
zation of interests deemed more important than public health.  
Results 
All of the techniques of neutralization proposed by Sykes and Matza (1957) were 
identified in the empirical material when analyzing the ways Martin Shkreli justi-
fied Turing’s business activities. The results are presented below in relation to 
each technique of neutralization.  
The denial of responsibility 
Sykes & Matza (1957: 667) considered there to be a perceived line between ac-
tions taken with intent and those for which the individual bears no responsibility. 
For this reason, the condemnation of an individual may be ineffective if the con-
demned person justifies his criminal actions by claiming these to have been de-
pendent on external forces or negative influences in the peer group. In using such 
claims, the individual portrays himself as being powerless in relation to his cir-
cumstances by viewing himself more as a victim than a decision-maker, which 
enables the individual to deviate from societal norms without actively breaking 
these norms through his criminal behavior (Ibid.). This strategy was identified 
during an interview at CNBC (2015) when Shkreli was confronted in an inter-
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view with Hillary Clinton’s accusation that Turing had damaged the drug market. 
During her presidential campaign, Clinton had stressed the need for increased 
pricing controls on the drug market (Hurst, 2017: 106). When asked if he had an-
ticipated this negative attention, Shkreli answered: “You know, at the end of the 
day there have been much larger drug price increases by much bigger drug com-
panies” (CNBC, 2015). From this statement, it is evident that Shkreli is attempt-
ing to shift the negative attention in the direction of competitors on the drug mar-
ket, by framing his company as being a comparatively insignificant, small-scale 
organization.  
 Another use of this strategy was identified during the Forbes (2015) Healt-
hcare Summit. When confronted with the fact that patients’ access to Daraprim 
had been reduced following the price increase, Shkreli’s answer was “We have 
done everything possible to make sure everyone can get the drug. This is the prior 
manufacturer’s fault” (Ibid.). This statement could be interpreted as a form of  
denial of responsibility with Shkreli shifting the blame onto the prior manufactur-
ers of Daraprim, circumstances which Shkreli portrays himself as being com-
pletely powerless to influence as CEO of Turing. These two statements represent 
clear examples of shifting responsibility onto external negative influences in the 
pharmaceutical industry, thereby justifying Turing’s actions as not being in 
breach of societal norms. A different form of shifting the blame was utilized by 
Shkreli when interviewed in a segment published by the news television channel 
Bloomberg (2016). Shkreli shared his view on the cause of high healthcare ex-
penditures for American citizens in the following manner: 
“Drug pricing is only a small part of healthcare expenditures. Physicians are the biggest part. We 
don’t talk about physicians. Their prices are rising as fast or faster than drug prices. As are hos-
pitals and medical device companies. So, if you want to pick on drug companies, the drugs are 
actually the best cost-effective solution for healthcare” (Bloomberg, 2016). 
Here, Shkreli utilized the economic term cost-effective to rationalize the decision-
making of his company. In addition, Shkreli acknowledges that healthcare ex-
penditures constitute a problem in the USA. However, this could also be inter-
preted as a strategy whereby Shkreli denies responsibility by framing medical 
equipment, hospitals, and health practitioners as the major cause of economic 
harm to the healthcare system, rather than pharmaceutical drugs.  
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The denial of injury 
According to Sykes and Matza (1957: 667f), individuals can neutralize the 
wrongfulness of their behavior by evaluating the harmful consequences of the 
criminal act. The individual may view his crime as harmless by separating his ac-
tions from other types of crimes where the victims’ injuries are clear. The denial 
of injury is completely open for interpretation, since the individual may believe 
his actions to have been harmless despite information pointing to the opposite. In 
the Bloomberg (2016) interview, Martin Shkreli was confronted with the fact that 
drug prices were increasing at a faster rate than the cost of living in the USA. The 
reporter was concerned about insurance companies paying high costs for Turing’s 
drugs having negative nation-wide effects on health insurance over time. Shkreli 
responded to this criticism by saying, “I think what happens is that we learn as a 
society that what we prize in life is our health. And we are going to spend more 
and more on our health than ever before. And that’s a good thing. I think it’s a 
mark of a civilized country” (Ibid.). Shkreli not only denies that Turing’s busi-
ness model runs the risk of harming the entire American health insurance system, 
but he also portrays this harm as a positive sign of the nation’s development. By 
using this strategy, Shkreli tries to direct the focus away from the potential harm 
of Turing’s drug prices to instead portray vast medical expenses as a desirable 
ideal. The perception that corporate misbehavior does not harm consumers was 
also identified as an important rationalization for decisions to commit corporate 
crime among MBA students in the study by Piquero et al. (2005: 181). 
The denial of the victim 
The condemned individual may neutralize his or others’ aversion to his criminal 
acts by portraying the behavior as being appropriate in light of the circumstances 
of a specific situation (Sykes & Matza, 1957: 668). Denial of the victim may oc-
cur when the individual attempts to justify the harm inflicted by portraying the 
victim as a wrongdoer. Additionally, the individual may instead deny the victim’s 
existence if the victim was physically absent during the criminal act (Ibid.). When 
Shkreli was interviewed by a reporter from Vice (2016), he was asked to respond 
to reports from healthcare representatives of a lack of Daraprim at hospitals. 
Shkreli answered “There are five thousand hospitals in the US. There are only a 
few thousand people that get this illness to begin with. So, most hospitals will ac-
tually never see anyone with this illness” (Ibid.). Here Shkreli is attempting to 
portray patients with toxoplasmosis or HIV that were harmed by Turing’s restric-
tive distribution system as an abstract phenomenon and is thereby denying their 
existence. Shkreli employed the same strategy in the Bloomberg (2016) interview 
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when asked if the price increase for Daraprim meant negative consequences for 
individuals who needed the medication but who would be unable to afford it. He 
answered that “There aren’t consequences, they have insurance. I don’t know if 
you’re familiar with healthcare insurance. Ninety percent of Americans have it.” 
(Ibid.). This statement is correct, since according to estimates made by the Na-
tional Center for Health Statistics (NCHS, 2016) 87 percent of adults aged 18 to 
64 in the USA had health insurance in 2015. Shkreli’s statement also denies the 
existence of consumers affected by structures of inequality and supports Croall’s 
(2007: 100f) view of consumers living in poverty as more vulnerable to harmful 
corporate activity than wealthier groups in society, since the price increase of 
Daraprim had the most impact on people lacking health insurance and those 
whose health insurance that only covered part of the cost of the drug. 
The condemnation of the condemners 
The condemnation of the condemners is a strategy whereby individuals shift the 
focus from their own acts by emphasizing the motives and behaviors of those re-
acting negatively (Sykes & Matza, 1957: 668). The strategy might entail the ac-
cusers being portrayed as hypocrites, criminals, vengeful or corrupt. When 
Shkreli was asked whether he had put Turing at risk of governmental actions by 
enraging the public, Shkreli answered that he was “… learning at a young age 
that the government in many ways is an apparatus of vengeance. To be a little 
cynical about it” (Bloomberg, 2016). During the interview, Shkreli framed going 
against the government in a similar way, as can be seen from the following 
statement:  
“We have an administration that is very thuggish and bullish when it comes to companies. They 
look at them as targets and people as well, as targets to shake down in essence. And actually en-
forcing justice is not their goal. I think their goal is to make a name for themselves, to extract 
these billion-dollar settlements. And one has to tread very carefully and that’s why some of the 
greatest businesspeople have kept the lowest profiles” (Bloomberg, 2016). 
Here Shkreli chose to frame the scandal as a conflict with government officials, 
portraying his accusers as vengeful, corrupt and power-hungry individuals on a 
hunt for vulnerable entrepreneurs. Shkreli attempted to shift the negative attention 
away from Turing’s actions by portraying his accusers as scheming politicians 
exploiting populistic strategies. In doing this, Shkreli was once again trying to de-
flect the focus away from the topic under discussion, namely Turing’s actions, to 
instead direct it at power-hungry politicians who were trying to gain popularity 
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by attacking easy targets such as himself. Interestingly, Benson (1985: 601) 
found antitrust and fraud offenders to be more prone to accusing prosecutors of 
having ulterior, self-interested motives than other types of white-collar offenders.  
The appeal to higher loyalties 
The appeal to higher loyalties constitutes a technique whereby the individual neu-
tralizes social controls by referring to the criminal acts as a personal sacrifice 
made in favor of the demands of the social group to which the individual belongs, 
rather than the demands of society at large (Sykes & Matza, 1957: 669). When 
asked why Daraprim should be an expensive drug, Shkreli answered that “Our 
shareholders expect me to make as much money as possible for them and that’s 
the ugly dirty truth” (Forbes, 2015). Shkreli frames the controversial price in-
crease as being a consequence of the economic demands of the group to which 
Shkreli belongs, namely the capitalist pharmaceutical industry. Additionally, hav-
ing a higher belief in profit as the most important goal of a pharmaceutical com-
pany predicted decisions to commit corporate crime among the MBA students 
who participated in the study by Piquero et al. (2005: 176). Shkreli further elabo-
rated on the demands of the pharmaceutical industry when he was asked whether 
he would have acted differently if he had the chance to turn back the clock: 
“I could have raised it higher and made more profits for shareholders, which is my primary duty. 
And again, no one wants to say it, no one’s proud of it but you know this is a capitalist society, a 
capitalist system, and capitalist rules. And my investors expect me to maximize profits. Not to 
minimize them or go half or seventy percent. But to go a hundred percent of the profit curve that 
we’re all taught in MBA class” (Forbes, 2015).  
By referring to his education and profession, Shkreli emphasizes that the price 
increase was not a rejection of laws or social norms, just part of his job descrip-
tion in a society built on collective capitalist values. Shkreli also rationalizes his 
actions by claiming that his profession entails certain expectations from company 
shareholders. The appeal to higher loyalties has been viewed as relevant in rela-
tion to business markets in which profit maximization, loss minimization, and in-
creasing market share are viewed as producing benefits for society (Schoultz & 
Flyghed, 2016: 184). When Shkreli was asked whether ethics had any influence 
on his decision-making with regard to Turing’s drug pricing strategies, he gave 
the following answer: 
“As a capitalist, it’s your favorite thing. It’s pricing power. And at the end of the day, if you 
want all corporations to not have the obligation to maximize shareholder duty, we should take a 
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big old vote and have the senate and congress change the law. But right now, that’s the law and 
our job as executives of companies, to maximize shareholder’s duty. You know, last time I read 
carefully the laws, one’s general conception of ethics are generally not in play here” (Forbes, 
2015). 
According to Glasbeek (2002: 147, 158ff), corporations are created with the capi-
talistic goal of profit-maximization by corporate law. This main purpose of the 
capitalistic corporate structure provides corporate actors with immunity from re-
sponsibility and facilitates decisions that maximize profit even when they are act-
ing on the wrong side of the law or going against the interests of the larger collec-
tive (Ibid.). The profit logic is very apparent in Shkreli’s justifications, he re-
turned to the same reasoning when confronted with not reducing the cost of Dar-
aprim to the initial price level after publicly promising to do so: 
“We have shareholders just like every other company. And our shareholders want us to maxim-
ize our profits and lowering the price of our product is in direct contrast to achieving that objec-
tive. Under Delaware law, companies are by law required to maximize opportunities for share-
holders. Especially to maximize them when there is a conflict of doing something good for 
yourself versus doing something good for your shareholders. By law, you absolutely have to do 
what’s good for your shareholders” (Forbes, 2015). 
In Shkreli’s case, it is clear that Glasbeek’s (2002: 158ff) view of profit maximi-
zation as a rational justification for harmful corporate behavior also is true for the 
pharmaceutical industry. Shkreli rationalizes his actions by framing his duty to 
shareholders as having greater importance than public health and ethical de-
mands. However, Shkreli does not deny that the pharmaceutical industry primari-
ly operates to serve capitalist interests. According to Shkreli, his organization and 
the state share the same interests, since state regulations have failed to restrain 
Turing’s harmful business activity. 
 Despite his prior standing on ethical considerations, Shkreli attempts another 
way of framing the issue in the interview with Vice (2016) when the reporter 
asked for his view on the public perception of him as an evil person. Shkreli an-
swered, “We sell our drugs for seven and fifty a pill to Walmart, to Exxon Mobil, 
to all these big companies. And they pay full price because fuck them, why 
shouldn’t they? And if I take that money and I’m using it to do research for dying 
kids, I think I’m a hero” (Ibid.). This statement could be interpreted as an attempt 
by Shkreli to bridge the gap between the capitalist demands of the drug industry 
and humanitarian interests, by framing himself as some form of Robin Hood-
character, a philanthropist who charges big companies for over-priced drugs in 
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order to help vulnerable patient groups. At the same time, he attempts to deflect 
accusations of causing harm by portraying the costs as being necessary to enable 
the conduct of research for the collective good. This form of appeal to higher loy-
alties is similar to the quasi-philanthropic arguments of companies accused of 
criminal activities, as identified by Schoultz and Flyghed, (2016: 196), whereby 
harmful business activities are framed as benefitting society. Furthermore, 
Shkreli’s appeal to higher loyalties is noteworthy since most biotech company 
start-ups finance their research using money from investors rather than from pa-
tients and hospitals (New York Times, 2015b). 
Discussion & conclusion 
When accused of having inflicted social harm on vulnerable patient groups and 
the healthcare system, the CEO of Turing Pharmaceuticals, Martin Shkreli, justi-
fied Turing’s corporate conduct by employing all of the techniques of neutraliza-
tion proposed by Sykes and Matza (1957). Shkreli denied responsibility by shift-
ing the blame to other actors and framed both the victims of the Daraprim price 
increase and the injury to the nation’s healthcare system as non-existent. Shkreli 
condemned those accusing him of running a deviant business strategy by framing 
these persons as corrupt, power-hungry and vengeful. Shkreli also admitted that 
his company is driven by profit maximization, which he framed as a more im-
portant goal within the pharmaceutical industry than ethical considerations. 
Shkreli justified having a higher loyalty towards economic interests than to public 
health by referring to US laws and regulations concerned with the drug industry 
and to the economic demands of company research for the collective good. The 
latter justification is in line with longstanding claims made by the industry that 
high drug prices are necessary in order to carry out costly research and develop-
ment (Dukes et al., 2014: 215f; Kesselheim et al., 2016: 863).  
 Questions might be raised regarding having Martin Shkreli, and his use of 
neutralization techniques, represent the pharmaceutical industry. After all, there 
are drug companies that do not operate in this unethical manner and Turing 
pharmaceuticals could be viewed as a single, and extreme, case that is not repre-
sentative for the whole pharmaceutical industry. However, this type of harmful 
corporate behavior is sadly not unique. For example, the pharmaceutical compa-
ny Hoffman-La Roche has a long history of harmful business strategies, such as 
anti-competitive behavior on the drug market and increasing the original price of 
a drug by referring to falsified manufacturing costs (Glasbeek, 2002: 150ff). In a 
more recent case, the former CEO of Valeant Pharmaceuticals International, Mi-
chael Pearson, has yet to face any penalization for drug pricing and distribution 
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schemes similar to those of Turing (Reuters, 2017). Unethical drug pricing also 
exists in a Scandinavian context. In 2015, the Swedish New Therapies Council 
failed to force the sole provider of the drug eculizumab into lowering the high 
price of the drug (Dagens Medicin, 2018). Eculizumab is used when treating pa-
tients with the rare and life-threatening disease atypical hemolytic uremic syn-
drome and a year-long treatment with eculizumab for one adult Swedish patient 
has been estimated to cost 4.45 million Swedish Kronor (Ibid.). Bittle (2016: 295) 
has warned against reducing harms inflicted by corporations to single incidents 
caused by a few individuals, since this ignores the larger structure of corporations 
that cause similar incidents and prioritize profit over saving human lives. Thus, 
Shkreli’s justifications of Turing’s conduct during the Daraprim scandal could be 
viewed as representable of pharmaceutical companies that employ unethical pric-
ing strategies and harm vulnerable patient groups all over the world. Whereas 
other CEO:s have kept a lower profile, Shkreli’s candidness about the scandal 
provides a basis for a better understanding of how individuals in powerful posi-
tions within the pharmaceutical industry justify decisions that negatively affect 
both patient groups and the entire healthcare system. It could be argued that the 
techniques of neutralization employed by Shkreli are representable for individu-
als that commit corporate crime in general, as the capitalistic corporate system 
has been viewed as criminogenic by providing individuals with rational justifica-
tions for criminal or otherwise harmful acts (Glasbeek, 2002: 147). Applying val-
ues linked to economic interests, such as profit-maximization, enables individuals 
within these organizations to justify the decision to engage in business conduct 
that causes serious social harm. Efforts should be directed towards identifying 
public and social policy responses against harms caused by pharmaceutical com-
panies, since making corporations more accountable and transparent by changing 
the corporate structure has been viewed as likely to be more effective than apply-
ing criminal or civil law (Hillyard & Tombs, 2007: 20).  
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